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Other Specific Nephropathies S59(r Z 0.273, p Z 0.044). Multivariate analysis confirmed that urinary
COL1A1 mRNA level is an independent predictor of serum creatinine
doubling (adjusted hazard ratio 1.023, p Z 0.016).
Conclusion: Urinary COL1A1 mRNA level is elevated in nephrotic patients
irrespective to the pathological diagnosis, and it correlates with proteinuria,
histological scarring, and inversely with renal function. Furthermore, urinary
COL1A1 mRNA level predicts renal function loss during follow up. Our results
suggest that urinary COL1A1 mRNA level may be used for risk stratification of
adult nephrotic syndrome.http://dx.doi.org/10.1016/j.hkjn.2015.09.0030006
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Background: Podocyte depletion is a characteristic feature of progressive
renal failure. We hypothesize that studying the podocyte mRNA level in uri-
nary sediment may provide diagnostic and prognostic information in adult
nephrotic syndrome.
Methods: We studied 25 patients with minimal change nephropathy (MCN),
25 with focal segmental glomerulosclerosis (FSGS), and 17 healthy controls.
The mRNA levels of nephrin, podocin and synaptopodin in urinary sediment
were quantified.
Results: There were significant differences in the urinary sediment nephrin
and podocin, but not synaptopodin, mRNA levels between diagnosis groups.
Post hoc analysis further shows that urinary nephrin mRNA levels of the MCN
group are lower than those in the control and FSGS groups, although the dif-
ference between MCN and FSGS Groups does not reach statistical signifi-
cance. The degree of proteinuria inversely correlates with urinary nephrin
mRNA levels in the MCN (r Z 0.526, p Z 0.007) as well as FSGS group
(r Z 0.521, p Z 0.008). For the FSGS group, the rate of renal function
decline significantly correlates with baseline urinary synaptopodin mRNA
levels (r Z 0.496, p Z 0.012).
Conclusion: Urinary nephrin and podocin mRNA levels are reduced in pa-
tients with MCN and probably FSGS, and the magnitude of reduction corre-
lates with the degree of proteinuria. Urinary synaptopodin mRNA levels
correlate with the subsequent rate of renal function decline in patients
with FSGS. Our result indicates that urine sediment podocyte mRNA levels
provide novel insights in the pathophysiology of nephrotic syndrome and
could be useful for risk stratification.http://dx.doi.org/10.1016/j.hkjn.2015.09.0040008
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Hyperuricemia is an independent risk factor for chronic kidney disease and
contributes to kidney fibrosis. In this study, we investigated the effect of
epidermal growth factor receptor (EGFR) inhibition on the development of
hyperuricemic nephropathy (HN) and the mechanisms involved. In a rat
model of HN induced by feeding a mixture of adenine and potassium
oxonate, increased EGFR phosphorylation and severe glomerular sclerosis
and renal interstitial fibrosis were evident, accompanied by renal dysfunc-
tion and increased urine microalbumin excretion. Administration of gefiti-
nib, a highly selective EGFR inhibitor, prevented renal dysfunction, reduced
urine microalbumin and inhibited activation of renal interstitial fibroblasts
and expression of extracellular proteins. Gefitinib treatment also inhibited
hyperuricemia-induced activation of the transforming growth factor-b1
(TGF-b1) and nuclear factor-kB (NF-kB) signaling pathways and expression
of multiple profibrogenic cytokines/chemokines in the kidney. Furthermore,
gefitinib treatment suppressed xanthine oxidase activity which mediates
uric acid production, and preserved expression of organic anion transporters
1 and 3, which promotes uric acid excretion in the kidney of hyperuricemic
rats. Thus, blocking EGFR can attenuate development of HN via suppression
of TGF-b1 signaling and inflammation, and promotion of the molecular
processes that reduce uric acid accumulation in the body.http://dx.doi.org/10.1016/j.hkjn.2015.09.0050015
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Objective: Glial cell line-derived neurotrophic factor (GDNF), a memberof
TGF-b superfamily, was testified to have protective effect on podocyte in
vitro. Helix B surface peptide (HBSP), derived from erythropoietin, displays
powerful tissue protection during kidney ischemia reperfusion (IR) injury
without erythropoietic side effects. The purpose of this study was to
explore the renoprotection effect of HBSP in puromycin aminonucleo-
side-induced nephrotic syndrome for the first time, and the change of
GDNF involved in.
Methods: Wistar rats were randomly divided into three groups, (1) Control
group (n Z 4); (2) PAN+vehicle group (n Z 6); (3) PAN+HBSP group
(n Z 8), which treated with HBSP (8 nmol/kg), 4 hours before the injection
of PAN (60 mg/kg) and every 24 hours after. Biochemical parameters, gene
expression and histology were assessed at 7 days.
Results: The levels of proteinuria significantly increased in rats with PAN-
induced nephrosis. Treatment with HBSP significantly prevented these dete-
riorations induced by PAN. Glomerular lesions, especially vacuolation of
podocytes, and the increase of desmin expression in PAN-treated rats
were significantly ameliorated by treatment with HBSP. The GDNF was
increased in in rats with PAN-induced nephrosis and increased further after
treated with HBSP. We also found activation of the RAS/ERK signaling
pathway in HBSP-treated rats.
Conclusion: HBSP could ameliorate proteinuria in PAN-induced nephrosis,
which might be due to the amelioration of podocyte injury. HBSP inhibited
the depletion of podocin. Increasing expression of GDNF and activation of
downstream RAS/ERK signaling pathway can be involved in the renoprotec-
tive effect of HBSP. GDNF might be involved in the renoprotective effect
of HBSP.
